Assessing the Long-Term Safety and Efficacy of Nivolumab Plus Chemotherapy for Broader Clinical Adoption in Advanced GI Cancers
Panelists discuss how the adoption of immunotherapy-chemotherapy combinations in clinical practice requires careful consideration of both long-term safety profiles and sustained efficacy data. A 5-year follow-up period generally provides valuable insights into delayed adverse events and durability of response, which helps inform risk-benefit assessments. The balance between safety and efficacy should be evaluated on a patient-specific basis, considering factors such as performance status, comorbidities, and tumor characteristics.
CN25_BTL_UGI_Seg04_Assessing
Video Player is loading.
- Does the long-term safety profile of nivolumab plus chemotherapy at 5 years provide sufficient reassurance for broader adoption in clinical practice?
- How does this balance with efficacy?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Overview of Study Design of the COCOON Trial
Clinical Insights: Experiences With Amivantamab-Lazertinib in EGFR-Mutant NSCLC
Managing 3rd-Line R/R FL: Recognizing Progression, Performing Rebiopsies, and Rechecking for CD20 Positivity
Overview of R/R FL: Focus on the 3rd-Line Setting and Beyond START
SWOG 80702: Impressions on the Efficacy Data
SWOG 80702: Overview of Study Design, Efficacy End Points, and Patient Characteristics
Epithelioid Sarcoma: Histological Features and Differential Diagnoses
Epithelioid Sarcoma: Overview and Presentation
Leveraging PSMA PET Imaging in Posttreatment Response Assessment: Evolving Practices and Data Insights
Decision-Making Factors in Choosing Combination Therapies in EGFR-Mutated NSCLC
Related Content
